NIH Charters Cancer Advisory Panel on Alternative Medicine

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 6
Volume 8
Issue 6

BETHESDA, Md-The National Institutes of Health (NIH) has chartered its Cancer Advisory Panel for Complementary and Alternative Medicine, limiting the group’s lifetime to 2 years unless it is formally renewed.

BETHESDA, Md—The National Institutes of Health (NIH) has chartered its Cancer Advisory Panel for Complementary and Alternative Medicine, limiting the group’s lifetime to 2 years unless it is formally renewed.

The panel was initially organized last November to advise the directors of the NIH, the National Cancer Institute, and the National Center for Complementary and Alternative Medicine. The 13-member panel assesses summaries of evidence and makes recommendations about future directions in research. It is chaired by Ernst Wynder, MD, of the American Health Foundation.

Recent Videos
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content